Cargando…

The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)—Data from POLISH MIS-C Registry

Background: Multisystem inflammatory syndrome (MIS-C) is a condition related to COVID-19. It’s most significant feature is cardiac involvement. Methods: We have analyzed data from 42 hospitals in the Polish MIS-C Registry. To compare the effect of GCS on fever, we formed two groups: the first treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gowin, Ewelina, Toczyłowski, Kacper, Sulik, Artur, Wysocki, Jacek, Januszkiewicz-Lewandowska, Danuta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870526/
https://www.ncbi.nlm.nih.gov/pubmed/35204900
http://dx.doi.org/10.3390/children9020178
_version_ 1784656779009851392
author Gowin, Ewelina
Toczyłowski, Kacper
Sulik, Artur
Wysocki, Jacek
Januszkiewicz-Lewandowska, Danuta
author_facet Gowin, Ewelina
Toczyłowski, Kacper
Sulik, Artur
Wysocki, Jacek
Januszkiewicz-Lewandowska, Danuta
author_sort Gowin, Ewelina
collection PubMed
description Background: Multisystem inflammatory syndrome (MIS-C) is a condition related to COVID-19. It’s most significant feature is cardiac involvement. Methods: We have analyzed data from 42 hospitals in the Polish MIS-C Registry. To compare the effect of GCS on fever, we formed two groups: the first treated with IVIG and the second treated with IVIG+GCS. Results: There were 111 boys and 56 girls; the mean age was 8.57 years. All the patients were treated with IVIG: 76 patients with IVIG only, and 91 patients with IVIG+GCS. There were no statistically significant differences between the groups regarding age, gender, BMI, or inflammatory markers. Methylprednisolone was the most common drug (80%). Echocardiographic abnormalities on admission were more prevalent in the IVIG+GCS group. Mean time from IVIG infusion to subsidence of fever was 1.1 days, and 1.5 for those in the IVIG+GCS group. Conclusions: GCS are commonly used in the treatment of MIS-C patients in Poland. Various GCS regimens are used, from a single dose to a month-long therapy. Children with lower lymphocyte levels and cardiac abnormalities on an echocardiographic examination performed on admission were more likely to receive GCS+IVIG. The effect of GCS is difficult to access as patients were not randomly assigned to receive the treatment.
format Online
Article
Text
id pubmed-8870526
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88705262022-02-25 The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)—Data from POLISH MIS-C Registry Gowin, Ewelina Toczyłowski, Kacper Sulik, Artur Wysocki, Jacek Januszkiewicz-Lewandowska, Danuta Children (Basel) Article Background: Multisystem inflammatory syndrome (MIS-C) is a condition related to COVID-19. It’s most significant feature is cardiac involvement. Methods: We have analyzed data from 42 hospitals in the Polish MIS-C Registry. To compare the effect of GCS on fever, we formed two groups: the first treated with IVIG and the second treated with IVIG+GCS. Results: There were 111 boys and 56 girls; the mean age was 8.57 years. All the patients were treated with IVIG: 76 patients with IVIG only, and 91 patients with IVIG+GCS. There were no statistically significant differences between the groups regarding age, gender, BMI, or inflammatory markers. Methylprednisolone was the most common drug (80%). Echocardiographic abnormalities on admission were more prevalent in the IVIG+GCS group. Mean time from IVIG infusion to subsidence of fever was 1.1 days, and 1.5 for those in the IVIG+GCS group. Conclusions: GCS are commonly used in the treatment of MIS-C patients in Poland. Various GCS regimens are used, from a single dose to a month-long therapy. Children with lower lymphocyte levels and cardiac abnormalities on an echocardiographic examination performed on admission were more likely to receive GCS+IVIG. The effect of GCS is difficult to access as patients were not randomly assigned to receive the treatment. MDPI 2022-02-01 /pmc/articles/PMC8870526/ /pubmed/35204900 http://dx.doi.org/10.3390/children9020178 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gowin, Ewelina
Toczyłowski, Kacper
Sulik, Artur
Wysocki, Jacek
Januszkiewicz-Lewandowska, Danuta
The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)—Data from POLISH MIS-C Registry
title The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)—Data from POLISH MIS-C Registry
title_full The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)—Data from POLISH MIS-C Registry
title_fullStr The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)—Data from POLISH MIS-C Registry
title_full_unstemmed The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)—Data from POLISH MIS-C Registry
title_short The Role of Glucocorticoids in the Treatment of Multisystem Inflammatory Syndrome (MIS-C)—Data from POLISH MIS-C Registry
title_sort role of glucocorticoids in the treatment of multisystem inflammatory syndrome (mis-c)—data from polish mis-c registry
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870526/
https://www.ncbi.nlm.nih.gov/pubmed/35204900
http://dx.doi.org/10.3390/children9020178
work_keys_str_mv AT gowinewelina theroleofglucocorticoidsinthetreatmentofmultisysteminflammatorysyndromemiscdatafrompolishmiscregistry
AT toczyłowskikacper theroleofglucocorticoidsinthetreatmentofmultisysteminflammatorysyndromemiscdatafrompolishmiscregistry
AT sulikartur theroleofglucocorticoidsinthetreatmentofmultisysteminflammatorysyndromemiscdatafrompolishmiscregistry
AT wysockijacek theroleofglucocorticoidsinthetreatmentofmultisysteminflammatorysyndromemiscdatafrompolishmiscregistry
AT januszkiewiczlewandowskadanuta theroleofglucocorticoidsinthetreatmentofmultisysteminflammatorysyndromemiscdatafrompolishmiscregistry
AT gowinewelina roleofglucocorticoidsinthetreatmentofmultisysteminflammatorysyndromemiscdatafrompolishmiscregistry
AT toczyłowskikacper roleofglucocorticoidsinthetreatmentofmultisysteminflammatorysyndromemiscdatafrompolishmiscregistry
AT sulikartur roleofglucocorticoidsinthetreatmentofmultisysteminflammatorysyndromemiscdatafrompolishmiscregistry
AT wysockijacek roleofglucocorticoidsinthetreatmentofmultisysteminflammatorysyndromemiscdatafrompolishmiscregistry
AT januszkiewiczlewandowskadanuta roleofglucocorticoidsinthetreatmentofmultisysteminflammatorysyndromemiscdatafrompolishmiscregistry